• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Amorcyte

edit

Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR–001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and other services for the cell therapy industry, to provide Amorcyte with a pharmaceutical grade cGMP manufactured product that can be distributed commercially. Amorcyte was founded by Andrew Pecora, M.D., Chairman of The John Theurer Cancer Center at Hackensack University Cancer Center, with initial investment by Novitas Capital and Colt Ventures.

Milestones

edit

• 
  Amorcyte added Hans Mueller as Chairman.
  Posted 7/14/11 at 6:06pm
• 
  Amorcyte added Andrew L. Pecora as Andrew L. Pecora.
  Posted 7/14/11 at 6:06pm
• 
  Amorcyte was acquired by NeoStem. (7/14/11)
  Posted 7/14/11 at 6:16pm via neostem.com

Videos

Screenshots

edit

Sources

1. NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction (neostem.com) [edit]